Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: Making a silk purse from a sow's ear

Thorax

Volumn 68, Issue 4, 2013, Pages 309-310

  Wells, Athol U ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CARBON MONOXIDE; PIRFENIDONE;

CLINICAL EVALUATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DYSPNEA; EDITORIAL; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SPIROMETRY;

EID: 84875208959     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2012-202640     Document Type: Editorial

References (19)

1. Raghu G, Anstrom KJ, King TE Jr, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisolone, azathioprine and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366: 1968-77.
2. Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7. (Pubitemid 37088594)
3. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42. (Pubitemid 37088595)
4. Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-8. (Pubitemid 37088596)
5. King TE Jr, Safrin S, Starko KM, et al. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-7. (Pubitemid 41724573)
6. Jegal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639-44. (Pubitemid 40365421)
7. Peelen L, Wells AU, Prijs M, et al. Fibrotic idiopathic interstitial pneumonias: mortality is linked to a decline in gas transfer. Respirology 2010;15:1233-43.
8. Corte TJ, Wort SJ, Macdonald PS, et al. Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology 2012;17:674-80.
9. Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in idiopathic pulmonary fibrosis versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011;38:176-83.
10. Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-6.
11. du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:459-66.
12. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary end-points in phase 3 clinical trials. Am J Respir Crit Care Med 2012;185:1044-8.
13. Richeldi L, Ryerson CJ, Lee JS, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67: 407-11.
14. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
15. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
16. Wells AU, King AD, Rubens MB, et al. Lone CFA: a functional-morphological correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997;155:1367-75. (Pubitemid 27172785)
17. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005;353:2229-42. (Pubitemid 41697286)
18. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005;353: 2285-7. (Pubitemid 41699756)
19. du Bois RM, Weycker D, Albera C, et al. Forced Vital Capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382-9.